Antibody buffering of systemically administered lysozyme.
OBJECTIVE
To assess the ability of an anti-lysozyme antibody to stabilize the plasma pharmacokinetics of lysozyme through a 'buffering' effect.


METHODS
Hen egg lysozyme was radiolabeled with (14)C and infused with or without the murine anti-lysozyme antibody D1.3 into the jugular vein of rats. The dosages of antibody and lysozyme were varied, and the antibody and lysozyme were administered either together or in separate infusions.


RESULTS
Buffering of lysozyme with an equimolar amount of D1.3 more than doubled the plasma half-life of lysozyme and addition of more antibody buffer prolonged the half-life to an even greater extent. D1.3 bound lysozyme that was infused several minutes after the D1.3 administration, indicating that D1.3 can be charged with drug in vivo.


CONCLUSIONS
Antibody buffering of monovalent therapeutic enzymes is possible and may have potential for clinical use.
O'Hear
Carol
C
Children's Hospital Boston, Boston, MA, USA.
Foote
Jefferson
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000494:pharmacology*; D000936:Antigen-Antibody Complex / Q000097:blood; D000937:Antigen-Antibody Reactions; D002021:Buffers; D002645:Chickens; D004306:Dose-Response Relationship, Immunologic; D006207:Half-Life; D007262:Infusions, Intravenous; D007601:Jugular Veins; D008297:Male; D051379:Mice; D009113:Muramidase / Q000008:administration & dosage / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D002021:Buffers; D009113:Muramidase